[EXPLAINED] SA's new ARV medication is a game-changer, but there is a catch
The medication will be available in all provinces, with the full roll-out set to be completed by February 2020.
A new anti-retroviral (ARV) treatment is being launched by the Minister of Health, Dr Zweli MKhize on Wednesday.
The medication is being hailed as a game-changer in the fight against HIV/Aids, but it is not suitable for everyone.
The Deputy Director General (DDG) Health Programme in the Department of Health (DoH), Dr Yogan Pillay says the new three-in-one medication, dolutegravir (also known as DTG) drops the HI viral load of a patient much quicker.
"That's important because the quicker the viral load in a patient is reduced, the less chance that patient has of transmitting the virus to other people which means that we will have fewer new infections," says Pillay.
He says the new ARVs also have fewer side effects.
Listen below as Pillay explains the benefits of the new medication:
However, the medication can't be prescribed to everyone.
Pillay explains that the medication is not safe for women in the first six weeks of pregnancy, and can also lead to weight gain, particularly among African women.
ALSO READ: New antiretroviral drug to fight HIV, Aids
He also says that the new medication is for the treatment of HIV and not prevention, such as through use as a prophylactic.
He says the medication will be available in all provinces, with the full roll-out set to be completed by February 2020.
Those who wish to switch to the new ARVs need to consult with their medical practitioner.
"As long as the patient is virally suppressed and stable, the patient can switch.
He notes though that the existing ARV medication available in South Africa will not be discontinued.
"There is nothing wrong with the current regiment - there are just additional advantages to the new regiment," says Pillay.
Listen below as Pillay explains the consideration for those who might want to switch to the new medication: